Effect of the preventative allopurinol therapy within the framework of the peripheral blood stem cell donation

Nowadays the importance of the peripheral blood stem cell (PBSC) donation is continuously increasing. It is therefore crucial to determine all side effects for donors. This clinical trial deals with the preventative therapy using Allopurinol (300 mg/d) in order to prohibit the increase in serum uric acid as a result of rhG-CSF injections (10 g/kg Lenograstim over 5d). It comprises 72 donors (m/f: 57/15) passing through 3 examinations. The initial measurement of uric acid serves as clue to categorize the donors into groups. Donors with high uric acid are summarized as group 1 (30: m/f: 27/3), which obtained Allopurinol, whereas donors with normal uric acid are part of group 4 (42: m/f: 30/12). This group is additionally divided into groups 2 and 3 (dependent on the way of G-CSF administration). The mean serum uric acid of group 1 decreased from 7.01 to 5.03 mg/dl. In contrast, the value of group 4 increased from 5.16 to 6.15 mg/dl.